![]() |
|
|
Vol. 297, Issue 2, 516-523, May 2001
Institut National de la Santé et de la Recherche
Médicale Unité 481 and Centre Claude Bernard de Recherches
sur les Hépatites Virales (I.G., M.M., P.L., C.D., D.P., B.F.),
Service de Biochimie (M.-C.G.), Service Central d'Anatomie et de
Cytologie Pathologiques (C.D.), Hôpital Beaujon, Clichy, France;
and Pharmacie, Hôpital Bichat, Paris, France (G.P.)
Like other antihuman immunodeficiency virus dideoxynucleosides,
stavudine may occasionally induce lactic acidosis and perhaps lipodystrophy in metabolically or genetically susceptible patients. We
studied the effects of stavudine on mitochondrial DNA (mtDNA), fatty
acid oxidation, and blood metabolites in lean and genetically obese
(ob/ob) mice. In lean mice, mtDNA was depleted in liver and skeletal
muscle, but not heart and brain, after 6 weeks of stavudine treatment
(500 mg/kg/day). With 100 mg/kg/day, mtDNA transiently decreased in
liver, but was unchanged at 6 weeks in all organs, including white
adipose tissue (WAT). Despite unchanged mtDNA levels, lack of
significant oxidative mtDNA lesions (as assessed by long polymerase
chain reaction experiments), and normal blood lactate/pyruvate ratios,
lean mice treated with stavudine for 6 weeks had increased fasting
blood ketone bodies, due to both increased hepatic fatty acid
-oxidation and decreased peripheral ketolysis. In obese mice, basal
WAT mtDNA was low and was further decreased by stavudine. In
conclusion, stavudine can decrease hepatic and muscle mtDNA in lean
mice and can also cause ketoacidosis during fasting without altering
mtDNA. Stavudine depletes WAT mtDNA only in obese mice. Fasting and
ketoacidosis could trigger decompensation in patients with incipient
lactic acidosis, whereas WAT mtDNA depletion could cause lipodystrophy
in genetically susceptible patients.
This article has been cited by other articles:
![]() |
I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Note, C. Maisonneuve, P. Letteron, G. Peytavin, F. Djouadi, A. Igoudjil, M.-C. Guimont, M. Biour, D. Pessayre, and B. Fromenty Mitochondrial and Metabolic Effects of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Mice Receiving One of Five Single- and Three Dual-NRTI Treatments Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3384 - 3392. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Sekhar, F. Jahoor, A. C. White, H. J. Pownall, F. Visnegarwala, M. C. Rodriguez-Barradas, M. Sharma, P. J. Reeds, and A. Balasubramanyam Metabolic basis of HIV-lipodystrophy syndrome Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E332 - E337. [Abstract] [Full Text] [PDF] |
||||